Fulphila (Pegfilgrastim)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Fulphila is a prescription drug that is used alongside cancer treatments. It decreases the risk of infection in people receiving drugs that weaken the immune system and is given to patients with non-myeloid malignancies with a significant incidence of febrile neutropenia.
Pegfilgrastim is a colony-stimulating factor (CSF) that acts as a bone marrow growth stimulant. It mimics naturally occurring hormones by binding to cells in the bone marrow to increase growth and replication. Fulphila's active component, Pegfilgrastim, is a pegylated form of granulocyte colony-stimulating factor (G-CSF). The augmentation of neutrophils enhances the body's defense against infections by restoring the function of the immune system.
Directions
The usual directions are to inject 6 mg under the skin once per chemotherapy cycle.
Ingredients
The active ingredient in Fulphila is pegfilgrastim.
Interactions
- Fulphiila has no known drug-drug interactions
Cautions
Fulphila should not be given 14 days before or 24 hours after administration of cytotoxic chemotherapy. Doing so may negate the effects of the drug.
Pediatric patients should receive a weight-based dose rather than a fixed dose.
Tell your doctor immediately if you feel pain in the left upper abdomen or the shoulder. These pains may be a symptom of an enlarged spleen that could lead to splenic rupture.
Stop this drug immediately if you experience trouble breathing, as this could be a sign of a hypersensitivity reaction or acute respiratory distress syndrome (ARDS).
Tell your doctor if you have a personal or family history of sickle cell disease.
Tell your doctor if you have a history of kidney disease before starting this drug.
Side Effects
Common adverse reactions may include:
- Acute myeloid leukemia
- Acute respiratory distress syndrome
- Aortitis
- Anaphylaxis
- Bone pain
- Capillary leak syndrome
- Glomerulonephritis
- Leukocytosis
- Myelodysplastic syndrome
- Pain in limb
- Rupture of spleen
- Sickle cell anemia with crisis
- Thrombocytopenia
References
Fulphila [package insert]. Zurich, Switzerland: Mylan; June 2018.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 14435
-
Product Reviews
